Hand, Foot and Mouth Disease Clinical Trial
Official title:
A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine
The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine.
This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine. 780 healthy infants of 6 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)& recombinant hepatitis B vaccine on day 0 and EV71 vaccine (second dose)& Group A meningococcal polysaccharide vaccine on day 30. The group II receive recombinant hepatitis B vaccine on day 0 and Group A meningococcal polysaccharide vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06063057 -
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
|
Phase 1/Phase 2 | |
Completed |
NCT04133584 -
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine
|
Phase 4 | |
Completed |
NCT03241030 -
Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial
|
Phase 2 | |
Completed |
NCT01255124 -
Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children
|
N/A | |
Completed |
NCT03873740 -
Immunogenicity and Safety of Two Different Commercial EV71 Vaccines
|
Phase 4 | |
Completed |
NCT05637229 -
A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
|
||
Recruiting |
NCT06146088 -
Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine
|
Phase 4 | |
Active, not recruiting |
NCT06209398 -
Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine
|
Phase 4 | |
Recruiting |
NCT01175915 -
A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Recruiting |
NCT01145664 -
A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease
|
N/A | |
Completed |
NCT01182532 -
A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Completed |
NCT03281174 -
Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine
|
N/A | |
Completed |
NCT03582761 -
Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71
|
Phase 4 | |
Completed |
NCT03903926 -
Efficacy Trial of a Commercial EV71 Vaccine
|
Phase 4 | |
Completed |
NCT02001233 -
A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
|
||
Completed |
NCT03909074 -
Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months
|
Phase 3 | |
Completed |
NCT01769794 -
Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study
|
N/A | |
Recruiting |
NCT01182025 -
A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
|
N/A | |
Recruiting |
NCT06263439 -
Surveillance of HFMD in Pediatric Outpatients
|
||
Not yet recruiting |
NCT05397587 -
An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell)
|
Phase 4 |